Benzinga··Soligenix, Inc.Soligenix Burns Through Cash as Rare Disease Pipeline Awaits Make-or-Break 2026 Trials
Soligenix reported zero 2025 revenue and $11.1M net loss. Company has $7.9M cash, seeking partnerships to fund operations through Q4 2026 pivotal trials.
SNGXPhase 3 clinical trialbiopharmaceutical